Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Sep, 2017 | Pages:
74 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Epstein-Barr Virus (HHV-4) Infections - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Epstein-Barr Virus (HHV-4) Infections - Pipeline Review, H2 2017, provides an overview of the Epstein-Barr Virus (HHV-4) Infections (Infectious Disease) pipeline landscape. Epstein-Barr virus (EBV), also known as human herpesvirus 4, is a member of the herpes virus family. It is one of the most common human viruses. EBV spreads most commonly through bodily fluids. EBV can also spread through blood and semen during sexual contact, blood transfusions, and organ transplantations. Symptoms of EBV infections include fatigue, fever, and inflamed throat, swollen lymph nodes in the neck, enlarged spleen, swollen liver and rash. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Epstein-Barr Virus (HHV-4) Infections - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Epstein-Barr Virus (HHV-4) Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Epstein-Barr Virus (HHV-4) Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Epstein-Barr Virus (HHV-4) Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 5, 2, 7 and 3 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 7, 2, 1 and 2 molecules, respectively. Epstein-Barr Virus (HHV-4) Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Epstein-Barr Virus (HHV-4) Infections (Infectious Disease). - The pipeline guide reviews pipeline therapeutics for Epstein-Barr Virus (HHV-4) Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Epstein-Barr Virus (HHV-4) Infections (Infectious Disease) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Epstein-Barr Virus (HHV-4) Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Epstein-Barr Virus (HHV-4) Infections (Infectious Disease) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Epstein-Barr Virus (HHV-4) Infections (Infectious Disease). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Epstein-Barr Virus (HHV-4) Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Epstein-Barr Virus (HHV-4) Infections - Overview Epstein-Barr Virus (HHV-4) Infections - Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes Epstein-Barr Virus (HHV-4) Infections - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Epstein-Barr Virus (HHV-4) Infections - Companies Involved in Therapeutics Development Advenchen Laboratories LLC Arno Therapeutics Inc bluebird bio Inc Cell Medica Ltd Epiphany Biosciences Inc Genocea Biosciences Inc Omeros Corp TC BioPharm Ltd Theravectys SA Viracta Therapeutics Inc Vironika LLC ViroStatics srl Epstein-Barr Virus (HHV-4) Infections - Drug Profiles apatinib mesylate - Drug Profile Product Description Mechanism Of Action R&D Progress AR-12 - Drug Profile Product Description Mechanism Of Action R&D Progress baltaleucel-T - Drug Profile Product Description Mechanism Of Action R&D Progress Cellular Immunotherapy for EBV Associated Malignancies - Drug Profile Product Description Mechanism Of Action R&D Progress Cellular Immunotherapy for EBV Associated PTLD - Drug Profile Product Description Mechanism Of Action R&D Progress Cellular Immunotherapy for Infectious Disease - Drug Profile Product Description Mechanism Of Action R&D Progress Cellular Immunotherapy for Infectious Disease - Drug Profile Product Description Mechanism Of Action R&D Progress Cellular Immunotherapy for Systemic Lupus Erythematosus, Epstein-Barr Viral Infections and Multiple Sclerosis - Drug Profile Product Description Mechanism Of Action R&D Progress Cellular Immunotherapy for Viral Infections - Drug Profile Product Description Mechanism Of Action R&D Progress Cellular Immunotherapy for Viral Infections Post-HSCT - Drug Profile Product Description Mechanism Of Action R&D Progress Cellular Immunotherapy to Target Calcineurin A for EBV Associated Post Transplant Lymphoproliferative Disorders - Drug Profile Product Description Mechanism Of Action R&D Progress Cellular Immunotherapy to Target LMP-1 and LMP-2 for Oncology and Infectious Diseases - Drug Profile Product Description Mechanism Of Action R&D Progress Cellular Immunotherapy to Target LMP1 for Epstein-Barr Virus Infections and Nasopharyngeal Cancer - Drug Profile Product Description Mechanism Of Action R&D Progress Cellullar Immunotherapy for Viral Infections and Fungal Infections - Drug Profile Product Description Mechanism Of Action R&D Progress EBViNT - Drug Profile Product Description Mechanism Of Action R&D Progress Epstein-Barr virus (virus like particle) vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress Epstein-Barr virus vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress GEN-007 - Drug Profile Product Description Mechanism Of Action R&D Progress MVA vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress OmnImmune - Drug Profile Product Description Mechanism Of Action R&D Progress Prelym - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Activate ZTA for Epstein-Barr Virus (HHV-4) Infections - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Inhibit CDK4, CDK6 and CDK9 for EBV Infections - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Inhibit EBNA1 for Epstein-Barr Virus (EBV) Infections - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Target GPR183 for Epstein-Barr Viral Infections and Osteoporosis - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit EBNA1 for Epstein-Barr Virus Infections - Drug Profile Product Description Mechanism Of Action R&D Progress valomaciclovir stearate - Drug Profile Product Description Mechanism Of Action R&D Progress Viralym-M - Drug Profile Product Description Mechanism Of Action R&D Progress Viroprev - Drug Profile Product Description Mechanism Of Action R&D Progress VRx-3996 - Drug Profile Product Description Mechanism Of Action R&D Progress Epstein-Barr Virus (HHV-4) Infections - Dormant Projects Epstein-Barr Virus (HHV-4) Infections - Product Development Milestones Featured News & Press Releases Dec 01, 2016: ViraCyte Announces Oral Presentations on Viralym-M Clinical Trial Results at the 58th American Society of Hematology Annual Meeting Aug 18, 2016: Vironika Secures Phase I SBIR Funding From NIH To Develop Inhibitors For EBV Lytic Reactivation Jun 02, 2014: Vironika Receives Phase II SBIR Grant From NIH To Continue The Development Of EBV Latency Inhibitors Mar 25, 2014: University of Birmingham launches trial to fight cancer caused by a common virus Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development for Epstein-Barr Virus (HHV-4) Infections, H2 2017 Number of Products under Development by Companies, H2 2017 Number of Products under Development by Universities/Institutes, H2 2017 Products under Development by Companies, H2 2017 Products under Development by Universities/Institutes, H2 2017 Number of Products by Stage and Target, H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 Number of Products by Stage and Route of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017 Epstein-Barr Virus (HHV-4) Infections - Pipeline by Advenchen Laboratories LLC, H2 2017 Epstein-Barr Virus (HHV-4) Infections - Pipeline by Arno Therapeutics Inc, H2 2017 Epstein-Barr Virus (HHV-4) Infections - Pipeline by bluebird bio Inc, H2 2017 Epstein-Barr Virus (HHV-4) Infections - Pipeline by Cell Medica Ltd, H2 2017 Epstein-Barr Virus (HHV-4) Infections - Pipeline by Epiphany Biosciences Inc, H2 2017 Epstein-Barr Virus (HHV-4) Infections - Pipeline by Genocea Biosciences Inc, H2 2017 Epstein-Barr Virus (HHV-4) Infections - Pipeline by Omeros Corp, H2 2017 Epstein-Barr Virus (HHV-4) Infections - Pipeline by TC BioPharm Ltd, H2 2017 Epstein-Barr Virus (HHV-4) Infections - Pipeline by Theravectys SA, H2 2017 Epstein-Barr Virus (HHV-4) Infections - Pipeline by Viracta Therapeutics Inc, H2 2017 Epstein-Barr Virus (HHV-4) Infections - Pipeline by Vironika LLC, H2 2017 Epstein-Barr Virus (HHV-4) Infections - Pipeline by ViroStatics srl, H2 2017 Epstein-Barr Virus (HHV-4) Infections - Dormant Projects, H2 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
